A sheep-derived Lactococcus garvieae and a probiotic agent thereof for combating Clostridium perfringens

By using probiotics of Lactococcus grenin strain LG1, the threat of C. perfringens to animal husbandry and human health was solved, the intestinal barrier function and bacterial structure were significantly improved, and the perfringens were inhibited. The invasion and proliferation of bacteria protects the health of animals.

CN117247859BActive Publication Date: 2024-11-22INNER MONGOLIA UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310831855.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-07
Publication Date
2024-11-22
Estimated Expiration
2043-07-07

AI Technical Summary

Technical Problem

Clostridium perfringens poses a serious threat to animal husbandry and human health. Existing prevention and treatment methods are difficult to effectively deal with mixed infections of drug-resistant strains and multiple serotypes, and intestinal capsular infection is difficult to control.

Method used

Using a specific Lactococcus garvieae strain LG1 (Lactococcus garvieae), liquid, powder or granular probiotic agents are isolated, identified and prepared, to enhance intestinal barrier function and inhibit the invasion of C. perfringens. and proliferation.

Benefits of technology

Lactococcus greninis LG1 significantly improved the intestinal barrier function, limited the invasion and proliferation of C. perfringens, promoted the recovery of intestinal microbiota structure, guaranteed the normal physiological function of animals, and in simulated infection model The survival rate and intestinal health indicators of mice were significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117247859B_ABST
    Figure CN117247859B_ABST
Patent Text Reader

Abstract

The invention discloses sheep-derived Lactococcus garvieae and a probiotic agent thereof for resisting Clostridium perfringens. The Lactococcus garvieae LG1 can improve the intestinal barrier function, restrict the invasion of Clostridium perfringens into the body, inhibit the proliferation of Clostridium perfringens, promote the recovery of intestinal flora structure, and ensure the normal physiological function of animals.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The patent of the present invention relates to the field of microbial technology, and specifically to a sheep-derived Lactococcus garvais and a probiotic agent thereof for combating Clostridium perfringens. Background Art

[0002] There are a variety of symbiotic bacteria living in the intestines of mammals, including major phyla such as Firmicutes, Actinomycetes, Bacteroidetes and Proteus. The intestinal microbial flora can be regulated by the immune system to maintain its homeostasis, and can also affect the immune system through immune responses and other pathways, and participate in regulating the homeostasis of the animal's internal environment and the barrier function of the intestinal mucosa, which is closely related to animal health. Since the intestinal mucosa has physical, chemical, immune and microbial barrier function characteristics at the same time, the intestinal mucosa is the first line of defense for the host to defend against foodborne pathogens.

[0003] Clostridium perfringens is an important foodborne pathogen that is transmitted between humans and animals, and poses a serious threat to the development of animal husbandry and human health. Therefore, infection caused by Clostridium perfringens is one of the major problems that plagues the animal husbandry industry and endangers human health. With the emergence of drug-resistant strains, the expansion of the drug-resistant spectrum, and mixed infections with multiple serotypes, the need for new prevention and treatment methods is more urgent. Clostridium perfringens can not only secrete a variety of exotoxins and invasive enzymes, but also form a capsule with strong invasiveness, which is both a component of the intestinal flora and one of the main causes of intestinal invasive infections.

[0004] In recent years, probiotics or microecological preparations have been widely used in animal husbandry as a new type of biological preparation to improve the intestinal microecology of animals, enhance immunity, and improve physiological functions and production performance. Intestinal symbiotic bacteria as microecological preparations have shown great application value in limiting pathogen infection. Therefore, studying new probiotics or microecological preparations and conducting detailed basic research and development and application on them is of great significance to promote the application of intestinal symbiotic bacteria biological preparations in animal husbandry. Summary of the invention

[0005] The first object of the present invention is to provide a Lactococcus garvieae strain LG1, the Lactococcus garvieae strain LG1 has a preservation number of CCTCC No.M20231114, and was deposited in the China Center for Type Culture Collection (CCTCC) on June 27, 2023, address: School of Life Sciences, Wuhan University, Wuhan City, Hubei Province, Postal Code: 430072, Telephone: 027-68754052.

[0006] The second object of the present invention is to provide a probiotic comprising the above-mentioned Lactococcus garvieae strain LG1, wherein the probiotic is in the form of liquid, powder or granules, and is prepared by conventional technical means and by adding auxiliary materials permitted in the field of microbial preparations; the probiotic is used to improve the intestinal barrier function and resist intestinal infection by Clostridium perfringens.

[0007] Advantages of the present invention: The present invention provides a Lactococcus garvieae strain LG1, which can improve the intestinal barrier function, limit the invasion of Clostridium perfringens into the body, inhibit the proliferation of Clostridium perfringens, promote the recovery of intestinal flora structure, and ensure the normal physiological function of animals. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0009] Figure 1 This is a frontal photograph of the colony morphology of the Lactococcus gasseri strain LG1 of the present invention.

[0010] Figure 2 This is the strain evolution tree of the Lactococcus gasseri strain LG1 of the present invention.

[0011] Figure 3 This is a Gram staining photograph of the Lactococcus garvieae strain LG1 of the present invention.

[0012] Figure 4 This is a growth pattern diagram of the Lactococcus gasseri strain LG1 of the present invention.

[0013] Figure 5 The graph shows the survival of the Lactococcus gasseri strain LG1 of the present invention under different environments, wherein A is the survival of the Lactococcus gasseri strain LG1 at different temperatures, B is the survival of the Lactococcus gasseri strain LG1 at different pH values, C is the survival of the Lactococcus gasseri strain LG1 at different NaCl concentrations, D is the survival rate of the Lactococcus gasseri strain LG1 in artificial gastric juice at pH=3.0 and pH=4.0, and E is the survival rate of the Lactococcus gasseri strain LG1 in artificial intestinal juice at different bile salt concentrations.

[0014] Figure 6 This is the survival rate of mice in the LG1 group and the model control group within 24 hours after oral administration of Clostridium perfringens.

[0015] Figure 7 The changes in body temperature and weight of mice in the LG1 group and the model control group after oral administration of Clostridium perfringens, where A represents the changes in body temperature and B represents the changes in body weight.

[0016] Figure 8 The permeability of the mouse intestine.

[0017] Fig. 9 is the expression level of Reg3β and Reg3γ in mouse intestinal tissue.

[0018] Fig.10 This is the PCA plot of mouse feces. DETAILED DESCRIPTION

[0019] The present invention will be further described in detail below by way of examples.

[0020] Example 1: Isolation, culture and identification of Lactococcus garvei strain LG1

[0021] Source of strains: The strains isolated in this example were derived from fresh intestinal mucosal tissue of Mongolian sheep, which were from a large-scale breeding farm in Inner Mongolia Autonomous Region.

[0022] Preparation of mixed culture medium: brain heart infusion broth, weigh 18.5g powder, yeast extract, weigh 5.0g powder, tryptone soy broth, weigh 15g powder, dipotassium hydrogen phosphate, weigh 2.5g powder, glucose, weigh 0.5g powder, L-cysteine ​​salt hydrate, weigh 0.6g powder, heat and dissolve in 1000mL distilled water, then add 1.5% agar, autoclave at 121℃ for 15min, cool to 50-55℃ after sterilization, add 50mL serum, 6.25μL vitamin K3, 11.1μL vitamin D, 52.63μL vitamin B12, 0.72μL vitamin B9, 100μL vitamin B6, and 1000μL trace salt.

[0023] Isolation of Lactococcus garvieae strain LG1: The fresh intestinal tissue of Mongolian sheep was collected and stored at low temperature and transported to the laboratory; it was placed on a clean bench, and the intestinal tissue was cut open with surgical scissors to expose the intestinal contents. The intestinal contents were gently scraped off with a scalpel, and the intestinal mucosa was scraped with a different knife and dissolved in 5 mL of mixed culture medium. After the mixed culture medium was diluted in multiples, it was spread on the mixed culture medium and cultured anaerobically at 37°C for 48 h. It was observed that the colony morphology was milky white and opaque, with a small circular shape, slightly raised, neat edges, and a smooth and shiny surface (such as Figure 1 Pick a single colony and continue culturing it in mixed culture medium, and repeat the plate coating until the colony is single.

[0024] Activation identification and preservation of strains: A single colony of Lactococcus garvieae was initially identified and inoculated into 5 mL of mixed culture medium and cultured anaerobically at 37°C for 48 h, and then subcultured twice with an inoculum volume of 1% (v / v). After activation, the strain was numbered LG1 for preservation, 16S rDNA sequencing was performed, and the sequence was uploaded to NCBI Blast for comparison. The strain evolution tree was made using the software MAFFT (e.g. Figure 2 Take 50 μL of bacterial solution and add 50 μL of sterilized 50% glycerol to preserve the strain at -80°C.

[0025] Amplification culture of Lactococcus garvieae LG1: The strain LG1 preserved in a -80℃ glycerol tube was streaked on a mixed solid culture medium plate for activation. After anaerobically culturing at 37℃ for 48 hours, a single colony was picked and inoculated into a mixed liquid culture medium. After anaerobically culturing at 37℃ for 48 hours, the amplified bacterial solution was obtained.

[0026] Gram staining of Lactococcus garvieae strain LG1: Take the bacterial solution of strain LG1 that has been amplified to the logarithmic growth phase, and perform staining and slide preparation according to the steps in the Gram staining kit instructions. After the smear is dried, perform microscopic examination and observe the color and morphology of the bacteria under an oil microscope. It is observed that the Gram staining microscopic examination results show blue-purple short streptococci, which proves that it is a Gram-positive bacterium (such as Figure 3 as shown).

[0027] Example 2: Determination of physiological properties of Lactococcus garvei strain LG1

[0028] Take out the frozen strain LG1 from the -80℃ refrigerator, streak it on the mixed culture medium plate, then pick out the single colony on the plate and activate it in an appropriate amount of mixed culture medium, inoculate it into a new mixed culture medium at 1% (v / v), and culture it in an anaerobic incubator at 37℃. Starting from the 0th hour, take out a tube of bacterial liquid every 1 hour and detect its absorbance at 600nm. The results show that the logarithmic growth period of Lactococcus garvei strain LG1 is between 2h and 4h (such as Figure 4 As shown); Pick a single colony on the plate and activate it in an appropriate amount of mixed culture medium, then inoculate it into a new mixed culture medium at 1% (v / v), and culture the culture solution at 16℃, 23℃, 30℃, 42℃, 49℃ and 56℃ under anaerobic conditions. After anaerobic culture for 24 hours, the absorbance at 600nm was detected. The results showed that Lactococcus garvei strain LG1 can survive well under 16℃-42℃ conditions (as shown Figure 5 A); pick a single colony on the plate and activate it in an appropriate amount of mixed culture medium, then inoculate it at 1% (v / v) in a new mixed culture medium with a pH value of 2, 3, 4, 5, 6, 7, 8, and 9, and culture it in an anaerobic incubator at 37°C. The results showed that Lactococcus garvei strain LG1 can survive and grow in an environment with a pH of 3-9 (as shown in Figure 5B); Pick a single colony on the plate and activate it in an appropriate amount of mixed culture medium, then inoculate it into a new mixed culture medium with concentrations of 0%, 1%, 3%, 5%, 7%, 9%, and 11% NaCl at 1% (v / v), and culture it in an anaerobic incubator at 37°C. The results showed that the Lactococcus garvei strain LG1 can survive and grow in an environment with a maximum NaCl concentration of 7% (as shown in Figure 5 C); pick a single colony on the plate and activate it in an appropriate amount of mixed culture medium, culture it in an anaerobic incubator at 37°C for 24h, take 1mL of bacterial solution to a sterile 1.5mL centrifuge tube, centrifuge it at 3000rpm / min, 4°C for 10min, discard the supernatant to collect the bacteria, add 1mL phosphate buffer solution (PBS solution for short) to resuspend the bacteria; take 500μL of bacterial suspension, add it to 4.5mL artificial gastric juice, mix it evenly, and culture it anaerobically at 37°C; take samples at 2h and 4h, spread them on the mixed culture medium plate after multiple dilution, and culture it anaerobically at 37°C for 24h, and calculate the survival rate of strain LG1. The experimental results show that the survival rate of strain LG1 in artificial gastric juice at pH=3.0 and pH=4.0 is more than 50%, indicating that strain LG1 can survive in the gastric acid environment (such as Figure 5 D); pick a single colony on the plate and activate it in an appropriate amount of mixed culture medium, culture it in an anaerobic incubator at 37℃ for 24h, inoculate it at 4% (v / v) in a new artificial intestinal fluid culture medium with bile salt concentrations of 0%, 0.3%, 0.5% and 1.0%, mix well, and culture it anaerobically at 37℃; take samples at 0h and 24h, spread them on the mixed culture medium plate after multiple dilution, and culture it anaerobically at 37℃ for 24h, and calculate the survival rate of strain LG1. The experimental results show that strain LG1 can tolerate gastric acid and artificial intestinal fluid with a certain bile salt concentration, and can reach the intestine after entering the host, and survive and colonize in the intestine to play its probiotic role (such as Figure 5 E).

[0029] Example 3: Experimental study on the treatment of mouse model infected with Clostridium perfringens by Lactococcus garvei strain LG1

[0030] Experimental animals: 30 SPF male C57BL / 6 mice, weighing 13-15 g, were purchased from the Experimental Animal Center of Inner Mongolia University and kept in an SPF animal room. The mice were randomly divided into three groups according to their initial weight, namely normal control group, LG1 group and model control group, with 10 mice in each group.

[0031] Construction of the mouse intestinal infection model of Clostridium perfringens: Mice in the LG1 group were gavaged with 100 μL (1×10 11CFU) of Lactococcus garvei strain LG1 were administered orally for six days; the mice in the normal control group and the model control group were administered orally with 100 μL of PBS solution every day for six days. After completion, the mice in the above three groups were fasted for 4 hours. Then, the mice in the LG1 group and the model control group were administered orally with 100 μL (5×10 9 The mice in the three groups were inoculated with Clostridium perfringens (CFU) (Accession No.: CN 1491), and then provided with drinking water and food 2 hours later.

[0032] 1. The survival of mice in the LG1 group and the model control group after oral administration of Clostridium perfringens within 24 hours was observed. Figure 6 As shown in Figure 2, the survival rate of mice in the LG1 group was significantly higher than that of mice in the model control group. At the same time, the body temperature and weight of the two groups of mice were tested every day. Figure 7 As shown, the body temperature and weight of both groups of mice decreased after oral administration of Clostridium perfringens. It was found that compared with the model control group, the body temperature of the mice in the LG1 group did not drop significantly, the weight loss was slower and the recovery was faster.

[0033] 2. Mouse intestinal permeability test: 20 hours after the administration of Clostridium perfringens, the three groups of mice were given gavage with dextran fluorescent probes. 24 hours after the administration of Clostridium perfringens, blood was collected from the eyes of the three groups of mice in the dark, and the serum was collected. The fluorescence intensity was detected by a fluorescent microplate reader to obtain the permeability of the mouse intestine. Figure 8 As shown, the intestinal permeability of LG1 group mice was significantly reduced compared with that of the model control group, indicating that pretreatment with the intestinal commensal Lactococcus gasseri strain LG1 reversed the increase in intestinal permeability caused by Clostridium perfringens.

[0034] 3. Detection of the expression of Reg3β and Reg3γ in mouse intestinal tissues: 24 hours after mice were infected with Clostridium perfringens, the duodenal tissues of the three groups of mice were collected, RNA was extracted, and the expression of Reg3β and Reg3γ was detected by qRT-PCR. Fig. 9 As shown, the results showed that compared with the model control group, the expression levels of Reg3β and Reg3γ in the duodenum of LG1 group mice were significantly increased, indicating that the intestinal commensal Lactococcus gasseri strain LG1 can improve the intestinal barrier function and help limit the excessive proliferation of Clostridium perfringens.

[0035] 4. Mouse feces 16S amplicon sequencing: Feces of three groups of mice were collected 24 hours after Clostridium perfringens infection, and the data were analyzed by PCA to determine the differences in intestinal microbial composition among the three groups of mice at the OTU level. Fig.10As shown, the differences and distances between samples are intuitively reflected. The closer the distance between samples in the PCA diagram, the smaller the difference between samples. The analysis results show that oral administration of intestinal commensal Lactococcus gasseri can restore the intestinal flora structure of mice.

[0036] The above are preferred embodiments of the present invention. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.

Claims

1. A Lactococcus garvieae LG1, characterized in that The deposit number of the Lactococcus garvieae LG1 is CCTCC No.M20231114.

2. A probiotic comprising the Lactococcus garvieae LG1 according to claim 1.

3. The probiotic according to claim 2, characterized in that The probiotic is in the form of liquid, powder or granules.

4. The probiotic according to claim 2 or 3, characterized in that Used to improve intestinal barrier function and resist intestinal infection by Clostridium perfringens.